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Abstract	
 
Objective:	To	systematically	review	current	evidence	regarding	the	minimum	acceptable	risk	
reduction	of	a	cardiovascular	event	which	patients	feel	would	justify	daily	intake	of	a	
preventive	medication.	
Methods:	We	used	the	Web	of	Science	to	track	the	forward	and	backwards	citations	of	a	set	of	
five	key	articles	until	15	November	2016.	Studies	were	eligible	if	they	quantitatively	assessed	
the	minimum	acceptable	benefit	-	in	absolute	values	-	of	a	cardiovascular	disease	preventive	
medication	among	a	sample	of	the	general	population,	and	required	participants	to	choose	if	
they	would	consider	taking	the	medication.		
Results:	Of	253	studies	screened,	we	included	22,	involving	a	total	of	17,751	participants:	6	
studied	Prolongation	of	Life	(POL),	12	Absolute	Risk	Reduction	(ARR),	and	14	studied	Number	
Needed	to	Treat	(NNT)	as	measures	of	risk	reduction	communicated	to	the	patients.	In	studies	
framed	using	POL,	39-54%	(average	48%)	of	participants	would	consider	taking	a	medication	if	
it	prolonged	life	<8	months,	and	56-73%	(average	64%)	≥8	months.	In	studies	framed	using	
ARR,	42-72%	(average	54%)	of	participants	would	consider	taking	a	medication	that	reduces	
their	5-year	CV	risk	by	<3%,	and	50-89%	(average	77%)	≥3%.	In	studies	framed	using	5-year	
NNT,	31-81%	(average	60%)	of	participants	would	consider	taking	a	medication	with	a	NNT	of	>	
30,	and	46-87%	(average	71%)	£30.	
Conclusions:	Many	patients	require	a	substantial	risk-reduction	before	they	consider	taking	a	
daily	medication	worthwhile,	even	when	the	medication	is	described	as	being	side-effect	free	
and	costless.		
	
Keywords:	Cardiovascular	Diseases,	Communication,	Decision-making,	Risk	Assessment,	Guideline	
Abbreviation:	CVD	Cardiovascular	Disease;	ARR	Absolute	Risk	Reduction;	NNT	Number	Needed	to	Treat;	POL	
Prolongation	of	Life	
	 	
 3 
Introduction	
Cardiovascular	disease	(CVD)	is	the	leading	cause	of	premature	death	and	reduced	disability	
adjusted	life-years	worldwide1	2.	Thus,	CVD	prevention	-	which	may	require	the	initiation	of	
lifelong	medication	aiming	at	modifying	specific	risk	factors	of	future	adverse	events3	-	has	
been,	and	will	continue	to	be,	a	public	health	priority.		
Clinical	Practice	Guidelines	(CPGs)	were	developed	to	assist	practitioners	and	patients	in	their	
decisions	about	appropriate	health	care	interventions.	However,	disease	preventive	guidelines	
face	a	crucial	challenge:	individuals	at	risk	often	feel	healthy	and	might	perceive	medications	as	
unnecessary,	particularly	those	having	uncertain	benefits	and/or	unpleasant	side	effects.	This	
challenge	can	lead	to	disagreement	between	how	guidelines	panel	and	patients	value	the	
benefits	and	harms	of	preventive	medications4.	For	instance,	while	guidelines	panels	may	
assume	that	the	benefits	of	a	preventive	intervention	outweigh	any	potential	harm,	individual	
patients	may	not	agree	with	their	trade-off.	When	there	is	uncertainty	in	the	trade-off	
between	benefits	and	harms	of	preventive	interventions5-7,	incorporation	of	patients’	
preferences	is	appropriate	and	important8.	Accordingly,	patients	may	decide	whether	to	accept	
or	reject	such	an	intervention	based	on	weighing	the	harms,	cost,	and	inconvenience	of	taking	
lifelong	medication	against	the	potential	long-term	benefits9	10.		
Despite	the	growing	acknowledgement	of	the	importance	of	patient	and	public	involvement	in	
the	development	of	CPGs,	current	CPGs	focus	primarily	on	the	medication	effectiveness	and	
often	fail	to	highlight	uncertainty	and	reconcile	patients	preferences	and	values	with	the	
guideline	recommendations11.	In	addition,	CPGs’	recommendations	are	often	used	as	a	
measure	of	the	quality	of	care	provided	by	clinicians	and	organisations12	13.		
For	instance,	the	most	recent	update	of	the	US	and	UK	CVD	risk	assessment	and	prevention	
guidelines	have	recommended	the	use	of	statins	among	people	previously	considered	at	low	
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risk	of	cardiovascular	disease,	setting	the	threshold	to	commence	statins	at	a	risk	of	a	CVD	
event	in	10	years	of	7.5%14	15.	However,	this	threshold	reflects	a	value	judgment	about	the	
balance	of	potential	harms	and	benefits	of	taking	statins,	which	some	patients	may	not	find	it	
justifiable	for	taking	statins.		
Therefore,	the	purpose	of	this	systematic	review	was	to	summarise	current	evidence	regarding	
the	minimum	acceptable	risk	reduction	of	a	cardiovascular	event	which	patients	feel	would	
justify	their	taking	daily	preventive	medication.	This	information	is	helpful	both	for	patients,	to	
actively	participate	in	the	decision-making	process16,	and	guidelines	panels	to	be	informed	of	
the	best	evidence	regarding	the	patients	values	and	preferences	in	making	trade-offs	between	
desirable	and	undesirable	consequences	of	such	an	intervention17.		
Methods	
A	protocol	for	this	systematic	review	was	developed	in	advance	(available	from	the	authors	on	
request).	
Information	Sources	and	Search	Methods	
We	developed,	with	the	help	of	a	medical	librarian	experienced	in	systematic	reviews,	a	search	
strategy	using	a	method	of	forward	and	backwards	citation	analysis.	We	used	Web	of	Science	
database	to	track	the	forward	and	backwards	citations	of	a	set	of	5	key	articles	until	15-
November-2016.	The	index	articles	for	our	citation	analysis	were	a	relevant	systematic	review18	
and	four	other	articles	identified	as	important	in	this	area9	10	19	20.	Searching	continued	
backward	and	forward	until	no	further	relevant	studies	are	found.	Citation	analysis	can	evade	
the	time-consuming	and	the	complex	nature	of	the	standard	search	strategies,	in	areas	where	
indexing	is	unlikely	to	retrieve	relevant	articles	with	an	acceptable	accuracy	rate21-23.		
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Eligibility	Criteria	
All	published	quantitative	primary	studies	were	eligible,	irrespective	of	the	study	design.	We	
included	studies	involving	adult	participants	who	made	a	decision	about	a	cardiovascular	
preventive	medication	whether	in	a	real-life	(actual)	or	a	hypothetical	(analogous)	scenario.		
Studies	were	eligible	if	they	assessed	the	minimum	acceptable	benefit	(CVD-risk-reduction)	of	a	
CVD	preventive	medication	among	a	sample	of	the	general	population,	and	provided	a	
quantitative	estimate	of	the	risk	reduction	(in	absolute	values)	required	by	patients	to	make	
daily	medication	worthwhile.	Absolute	risk	reduction	estimates	could	be	presented	in	the	
format	of	Prolongation-of-Life	(POL),	Absolute-Risk-Reduction	(ARR)	or	Number-Needed-to-
Treat	(NNT).	Studies	that	provided	a	descriptive	or	qualitative	estimate	of	risk	reduction	or	a	
quantitative	estimate	of	relative-risk-reduction	(without	baseline-risk)	were	excluded.		
Selection	of	Studies	
Two	authors	independently	screened	for	eligibility	the	titles	and	abstracts	of	identified	articles.	
We	retrieved	the	full-text	of	studies	that	potentially	met	the	eligibility	criteria.	From	the	full-
texts,	two	authors	independently	assessed	study	eligibility.	When	more	than	one	publication	of	
the	same	study	existed,	the	publication	with	the	most	complete	data	was	included.		We	
resolved	any	disagreement	by	discussion.	Reasons	for	exclusion	of	studies	were	documented.	
Data	Extraction	
Two	authors	independently	abstracted	data,	using	a	standardised	data	extraction	form.	The	
abstracted	data	included:	(1)	General:	title,	authors,	country,	language	and	year	of	publication,	
duplicate	publications,	sponsoring;	(2)	Participants:	sample	size,	baseline	characteristics,	and	
study	setting;	(3)	Scenario:	Hypothetical/Real,	type	of	risk	presentation	format	(POL,	ARR	or	
NNT),	method	for	eliciting	patients	preferences	(e.g.	discrete	choice),	medication	
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characteristics	(side	effects,	cost,	burden)	and	the	target	adverse	event	(mortality	or	
morbidity).		
Assessment	of	the	methodological	quality	and	Risk	of	Bias		
Included	studies	were	independently	assessed	by	two	authors	using	a	modified	version	of	the	
risk	of	bias	in	prevalence	studies	assessment	tool24,	which	includes	the	following	items:	
representation,	selection,	response	rate,	data	collection.	We	assessed	the	adequacy	of	each	
item:	'low',	‘unclear	or	‘high’	risk	of	bias.	
Data	Synthesis	
For	each	included	study,	we	extracted	or	calculated	the	average	5-year	ARR	or	NNT	or	POL	
required	by	the	participants	to	commence	a	CVD	preventive	medication.	We	reported	the	
ranges	(and	sample-size-weighted	averages)	of	5-year	ARR	or	NNT	or	POL	across	included	
studies.	A	meta-analysis	was	not	possible	due	to	the	heterogeneity	in	studies’	methods	and	
outcomes.	
Results	
We	screened	341	studies	(after	removal	of	duplicates),	of	which	238	were	classed	as	ineligible	
based	on	titles	or	abstracts.	Of	the	remaining	103	full-texts,	22	studies	with	a	total	of	17751	
participants	were	included	(Figure	1).	
Study	publication	dates	ranged	from	1995	to	2014;	study	sample-size	ranged	from	58	to	2978,	
with	an	average	of	807	participants.	Three	studies	were	internet-based	(1	US,	1	Norway,	and	1	
US	and	Norway),	while	the	remaining	studies	were	conducted	in	seven	countries:	6	UK,	5	
Denmark,	2	Norway,	2	New	Zealand,	2	US,	and	2	Canada.	The	22	included	studies	contributed	
63	estimates	of	minimum	acceptable	risk	reduction:	14	studies	contributed	28	estimates	in	the	
form	of	number-needed-to-treat	(NNT);	12	studies	contributed	22	estimates	in	the	form	of	
absolute-risk-reduction	(ARR)	and	6	studies	contributed	13	estimates	in	the	form	of	
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prolongation-of-life	(POL).	Participants	were	sampled	from	the	general	population	in	13	studies	
(59%)	and	from	primary-care	settings	in	9	studies	(41%).		Most	studies	elicited	participants’	
preferences	using	single-choice	questions	(n=16;	70%).	Other	methods	were	multiple-choice	
questions	(n=4),	iterative	process	(n=1)	or	trade-off	method	(n=1).	The	most	frequent	method	
of	data	collection	was	in-person	interviews	(n=12;	either	telephone	or	face-to-face);	the	
remaining	studies	used	surveys	to	collect	data	from	the	participants	(either	mailed	or	internet-
based	survey).	Characteristics	of	included	studies	are	shown	in	Table	1.	
The	results	of	the	quality	assessment	(Figure	2)	showed	that	half	of	the	studies	truly	
represented	the	general	population	(n=11).	Few	studies	(n=3)	had	a	response	rate	≥75%,	but	
random	selection	or	census	had	been	undertaken	in	most	studies	(n=17).	Data	had	been	
collected	using	the	same	methods	from	all	participants	in	most	included	studies	(n=17).		
Prolongation	of	Life	(POL)	
In	studies	which	presented	the	CV	benefits	framed	as	POL,	39-73%	of	the	participants	(average	
54%)	would	consider	taking	cardio-preventive	medication.	This	decreased	to	39-54%	(average	
48%)	when	we	only	considered	preventive	medications	that	prolonged	their	life	by	less	than	8	
months,	and	increased	to	56-73%	(average	64%)	when	the	analysis	was	restricted	to	studies	
presented	POL	equal	to	or	more	than	8	(Figure	3	and	eTable	1	in	the	Supplement).	
Absolute	risk	reduction	(5-year)		
In	studies	which	presented	the	CV	benefits	in	term	of	ARR,	42-89%	of	the	participants	(average	
60%)	would	consider	taking	the	CVD	preventive	medication.	This	decreased	to	42-72%	
(average	54%)	when	we	only	consider	studies	where	medication	reduced	the	5-year	absolute	
CV	risk	by	less	than	3%,	while	this	percentage	increased	to	50-89%	(average	77%)	when	we	
consider	studies	presented	ARR	equal	to	or	more	than	3%	(Figure	4	and	eTable	2	in	the	
Supplement).	
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Number	Needed	to	Treat	(5-year)	
In	studies	which	presented	the	CV	benefits	in	term	of	NNT,	31-87%	of	the	participants	(average	
64%)	would	consider	taking	cardio-preventive	medications.	This	decreased	to	31-81%	(average	
60%)	when	we	only	considered	studies	presented	a	medication	needed	to	be	taken	by	more	
than	30	persons	to	prevent	one	event	while	this	percentage	increased	to	46-87%	(average	
71%)	when	analysis	restricted	to	studies	presented	NNT	equal	to	or	less	than	30	(Figure	5	and	
eTable	2	in	the	Supplement).	
Factors	affecting	the	decision	to	commence	a	CVD	preventive	therapy	
Some	studies	explored	other	factors	that	would	affect	the	decision	to	take	a	medication.	These	
factors	help	to	explain	some	of	the	heterogeneity	observed	between	studies.		
Probabilistic	vs.	deterministic	‘fixed’	presentation	of	risk	
One	study	found	that	participants	were	more	likely	to	agree	to	a	CVD	preventive	therapy	when	
the	benefits	were	presented	as	a	certain,	short,	postponement	of	a	heart	attack	(182/456;	
40%)	compared	to	an	equal	average	but	uncertain	‘probabilistic’	long	postponement	of	the	
outcome	(153/452;	34%)19.	This	cognitive	bias	has	been	also	shown	by	Finegold	et	al25.	
Participants	presented	with	a	certain	1-year	life	gain	were	more	likely	to	accept	a	medication	
than	when	presented	with	a	10%	chance	of	10-year	life	gain	(56%	vs	45%)25.	However,	if	
participants	were	presented	with	two	gains	that	were	not	probabilistically	equivalent,	they	
preferred	the	therapy	that	provides	the	larger	gain	whether	presented	as	a	certain	or	uncertain	
benefit25.			
Positive	versus	Negative	framing	
Carling	et	al26	found	that	participants	were	more	likely	to	agree	for	a	CVD	medication	when	the	
risk	reduction	was	framed	negatively	(66%)	than	positively	(56%)	or	compared	to	informed	
information	that	included	positive	and	negative	format	together	(40%	and	46%	respectively).		
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Similarly,	Goodyear-Smith27	found	that	participants	were	more	likely	to	agree	to	taking	a	CVD	
medication	when	the	benefits	were	framed	negatively	(89%)	than	positively	(80%).		
Risk	presentation	format	
Stovring	et	al28	found	that	the	proportion	of	respondents	willing	to	take	a	medication	to	
prevent	CVD	was	higher	when	the	benefit	was	presented	as	either	ARR	(expressed	in	natural	
frequencies)	or	NNT	compared	to	POL.	Notably,	POL	was	found	to	have	the	least	concordance	
with	final	decisions	that	were	based	on	comprehensive	information	(ARR,	NNT,	RRR	and	
pictorial	presentation).	However,	another	study	found	more	patients	considered	taking	
medication	when	the	results	were	presented	as	ARR	(85%)	than	NNT	(67%)27.		Carling	et	al29	
compared	different	presentations	of	risk	reduction,	and	found	that	participants	were	more	
likely	to	consider	a	medication	when	the	benefit	presented	as	relative	risk	reduction,	but	
natural	frequencies	were	scored	the	highest	in	preference,	understanding	and	satisfaction	with	
the	presented	information,	and	confidence	in	the	decision.		
Adding	adverse	effects	
Fried	et	al30	asked	community-living	older	persons	their	willingness	to	agree	to	CVD	preventive	
medications	with	varying	degree	of	benefits	and	harms	(both	type	and	severity),	and	found	
that	about	a	half	of	the	respondents	who	initially	agreed	to	a	medication	with	average	benefit	
with	no	adverse	effects	were	unwilling	or	uncertain	about	taking	the	same	medication	if	it	was	
associated	with	even	mild	fatigue	and	nausea,	and	only	3	%	of	them	would	agree	to	a	
medication	that	had	adverse	effects	that	could	affect	their	activities	of	daily	living.		
Previous	history	or	high	risk	for	CVD			
The	presence	of	known	risk	factors	or	a	history	of	CVD	might	also	affect	the	decision	to	take	
the	medication.	For	instance,	Misselbrook	and	Armstrong31	found	that	patients	with	known	
high	blood	pressure	were	more	likely	to	agree	to	a	CVD	preventive	medication	than	
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participants	with	normal	blood	pressure,	which	has	been	also	found	by	McAlister	et	al32.	
Similar	findings	were	also	shown	by	Trewby	et	al33	comparing	participants	with	a	history	of	CVD	
and	taking	medications	to	patients	either	without	CVD	history	but	taking	a	preventive	
medication	or	without	CVD	history	and	taking	no	medication.	Similarly,	Dahl	et	al	found	that	
previous	history	of	myocardial	infarction	(OR:	2.5	95%CI	1.3-5.0),	and	elevated	cholesterol	level	
(OR:	1.9	95%CI	1.8-2.6)	significantly	increased	the	odds	of	consenting	to	medication34.	Fried	et	
al	found	that	participants	who	rated	their	health	as	poor/fair	were	more	likely	to	consider	
taking	a	medication	than	those	rated	their	health	as	excellent/very	good30.	However,	two	other	
studies	found	no	association	between	self-reported	health,	CVD	history	and	the	odds	of	
considering	taking	medication19	35.		
Participant	baseline	characteristics	
Male	gender	was	found	to	be	significantly	associated	with	considering	taking	a	medication	in	
Dahl	et	al34,	Halvorsen	et	al(2005)36,	and	Hudson	et	al3,	but,	not	in	Halvorsen	et	al(2007)19,	
Nexoe	et	al37,	and	Kristiansen	et	al35.	Older	age	and	higher	education	level	was	significantly	
associated	with	considering	taking	a	medication	in	Halvorsen	et	al(2007)19,	and	Kristiansen	et	
al35,	but,	not	in	Nexoe	et	al37,	Halvorsen	et	al(2005)36,	and	Dahl	et	al34.	
Perspective	of	Patients	vs.	Clinicians	
McAlister	et	al32	compared	the	minimum	gain	in	ARR	to	consider	taking	CVD	medication	
between	hypertensive	patients	(with	no	overt	CVD)	and	family	physicians,	and	found	that	
patients	demand	greater	benefits	before	agreeing	to	a	CVD	preventive	medication	compared	
to	physicians.	Similarly,	Steel38	found	that	the	gain	in	ARR	to	agree	to	an	antihypertensive	
medication	was	lower	among	consultant	physicians	than	general	practitioners,	and	highest	
among	the	general	public.	
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Discussion		
Results	of	the	22	studies	in	this	systematic	review	suggest	that	an	implicit	assumption	in	
cardiovascular	prevention	guidelines	-	that	participants	accept	the	amount	balance	between	
benefits	and	harms	-	may	not	be	concord	with	patient	preferences.	Even	in	the	studies	where	
people	were	presented	with	an	idealised	tablet	with	no	side	effects,	more	than	one-third	
stated	they	would	not	consider	taking	a	medication	that	could	prevent	their	5-year	absolute	
risk	of	a	cardiovascular	event	by	an	ARR	of	5%	or	more.	This	gain	is	rarely	achieved	by	CVD	
medication	(e.g.	statin	reduce	the	relative	risk	of	a	CVD	event	by	about	5-year	CV	absolute	risk	
by	about	30%39	40.	Moreover,	considerable	variations	were	observed	in	the	patients’	
preferences	of	the	minimum	acceptable	risk	reduction	of	cardio-preventive	medication.	
Several	factors	may	explain	the	wide	variation	in	patients’	preferences	both	within	and	across	
included	studies,	such	as	whether	patients	are	already	taking	a	preventive	medication,	and	the	
way	that	the	risk	reduction	has	been	communicated	to	the	participants	(e.g.	risk	presentation	
format	and	framing	effect).	A	recent	systematic	review	of	risk	communication	found	that	the	
various	risk	presentation	formats	might	have	different	effects	on	the	decision	to	consider	
taking	medication41.	However,	it	is	important	to	distinguish	between	the	persuasiveness	of	the	
risk	presentation	formats	and	the	clarity	and	understandability	of	the	format18.	Methods	used	
to	elicit	preferences	(e.g.	single-choice	options,	trade-off)	as	well	as	those	used	to	collect	data	
(face-to-face	interviews,	mailed	questionnaire)	may	also	contribute	to	variation	observed.	
Lastly,	the	characteristics	of	the	medication	presented	to	participants	may	also	have	affected	
their	decisions.	An	ideal	medication	(free	of	charge	and	no	side	effects)	is	more	likely	to	be	
accepted	compared	to	a	real-life	medication	with	costs	and	potential	side	effects.	
Thus,	when	patients’	preferences	vary	widely,	preventive	guidelines	should	be	wary	of	setting	a	
single	risk	threshold	for	the	initiation	of	a	preventive	treatment,	based	on	the	effectiveness	of	
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the	medication.	Any	threshold	point	or	range	should	be	based	on	the	balance	of	benefits	and	
downsides,	which	should	be	informed	by	patients’	value	and	preferences.	
Strength	and	Limitation	
The	heterogeneity	of	methods	used	to	assess	the	preferences,	including	trade-off	method,	
iterative	process,	and	single	choice	questions	is	both	a	strength	and	limitation	of	our	study.	The	
inclusion	criteria	meant	that	a	wide	variety	of	estimates	could	be	included	in	the	review,	but	
owing	to	this	heterogeneity	of	the	methods	and	outcomes,	we	could	not	calculate	quantitative	
summary	estimates	of	the	minimum	acceptable	risk	reduction,	which	is	common	in	systematic	
reviews	in	this	field17	42	43.		Moreover,	most	of	the	included	studies	have	not	been	designed	
primarily	to	assess	our	research	question,	but	to	examine	other	issues	such	as	response	to	
framing.	In	addition,	the	review	only	considers	those	factors	reported	in	the	included	studies.	
Another	potential	limitation	is	the	risk	of	missing	relevant	articles	because	of	the	use	of	citation	
analysis	as	a	search	strategy.	However,	studies	in	other	areas	suggest	the	accuracy	rate	of	this	
method	is	acceptable	(e.g.	using	citation	analysis,	Janssens	and	Gwinn retrieved	about	94%	
[75-100%]	of	all	included	articles	retrieved	using	traditional	method	in	10	meta-analyses23).	
Thus,	we	think	that	our	overall	results	and	conclusion	are	unlikely	to	be	affected.	
Implication	for	clinical	practice	
Patients’	preferences	should	be	considered	in	both	guideline	development	and	clinical	care.	
Patients	representatives	and	member	of	the	public	should	be	actively	involved	in	guideline	
development	panels44.	Future	guidelines	must	consider	more	than	the	evidence	of	medication	
effectiveness	in	establishing	treatment	thresholds:	Systematic	reviews	of	patients’	values	and	
preferences	should	also	be	conducted	to	inform	guideline	recommendations.	Given	the	
heterogeneity	in	individual	preferences,	guidelines	should	include	strategies	to	help	clinicians	
incorporate	patients’	preferences	and	values	to	make	informed	decisions.	This	can	be	achieved	
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by	promoting	choice,	providing	adequate	information	about	the	benefit	and	risks	of	
medication,	and	the	level	of	uncertainty	in	the	evidence,	and	highlighting	that	guideline	
recommendations	support,	but	do	not	substitute	for	clinical	judgment	and	individualised	
decision-making.	Visual	aids	(e.g.	icon	arrays	or	risk	pictograph)	to	communicate	risk	reduction	
might	be	used	since	evidence	shows	that	such	aids	improve	patients’	understanding	and	
satisfaction41.	This	also	implies	that	the	‘do	or	do	not’	style	of	recommendations	should	
generally	be	discouraged,	and	that	preference-sensitive	recommendations	should	not	be	used	
as	indicators	of	quality	of	care	(quality	measures).	
Clinicians	often	fail	to	accurately	identify	patient	preferences	–	a	problem	termed	silent	
misdiagnosis45,	and	hence	guidelines	should	include	tools	that	promote	shared	decision	making	
where	interventions	choices	can	be	tailored	not	only	to	patients’	clinical	characteristics	but	also	
to	their	values	and	preferences.	This	means	that	guideline	recommendations	should	be	used	as	
a	starting	point	for	the	individual	patient-clinician	decision-making	process.	In	addition,	patient	
versions	of	guidelines,	as	well	as	decision	aids	tools,	should	be	developed	and	disseminated	
along	with	the	guidelines.			
Implication	for	future	research	
This	systematic	review	highlights	the	need	for	standardising	the	key	measures	of	patient	
preferences	that	might	be	used	to	inform	guidelines.	Future	research	could	gain	from	using	
well-established	methods	for	preference	elicitation	used	in	other	disciplines	(e.g.	health	
economics)	to	develop	a	valid,	reliable,	and	sensitive	measure	of	patient	preferences	in	a	
medical	decision-making	context.	Moreover,	a	systematic	review	of	qualitative	studies	
regarding	the	factors	affects	the	individual	decision	of	CV	preventive	medication	is	also	
warranted.			
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Conclusion	
Even	for	a	side-effect	free,	costless	medication,	many	patients	require	a	substantial	risk-
reduction	to	consider	taking	a	preventive	medication.	However,	the	range	of	answers	is	very	
wide	with	some	accepting	any	gain,	and	other	not	willing	to	consider	medication	with	any	gain.	
Guidelines	and	clinical	consultations	need	to	account	for	both	these	average	and	individual	
values	in	setting	risk	thresholds.	
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Figures	
 
 
Figure	1:	Summary	of	flow	of	information	through	the	systematic	review	process	(PRISMA	Flow	
Diagram)	
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Figure	2:	Risk	of	bias	assessment:	authors’	judgments	about	each	risk	of	bias	item:	(A)	for	each	included	
study	(Risk	of	bias	graph);	and	(B)	presented	as	percentages	across	all	included	studies	(risk	of	bias	
summary).	
Representation:	was	the	sampling	frame	a	true	or	close	representative	of	the	target	population/general	population;	Selection:	
was	some	form	of	random	selection	used or	a	census	undertaken;	Non-response:	was	the	likelihood	of	non-response	bias	
minimal	(low	risk:	≥75%,	high	risk:	<75%);	Data	collection:	were	data	collected	directly	from	participants	and	if	the	same	mode	
of	data	collection	used	for	all	participants.	 
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Figure	3:	Minimum	acceptable	risk	reduction	in	cardiovascular	events	(expressed	as	Prolongation	of	
Life)	required	by	the	patients	to	justify	taking	daily	preventive	medication.	
Bubble	graph	showing	the	percentage	of	participants	of	included	studies	that	could	accept	taking	a	medication	against	the	
potential	prolongation	in	life	(in	months	in	logarithmic	scale)	for	such	a	medication;	the	bubble	area	represents	the	sample	
size.	
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Figure	4:	Minimum	acceptable	risk	reduction	in	cardiovascular	events	(expressed	as	ARR)	required	by	
the	patients	to	justify	taking	daily	preventive	medication	
Bubble	graph	showing	the	percentage	of	participants	of	included	studies	that	could	accept	taking	a	medication	against	the	5-
year	absolute	risk	reduction	in	cardiovascular	events	that	can	be	gained	by	such	a	medication;	the	bubble	area	represents	the	
sample	size.	
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Figure	5:	Minimum	acceptable	risk	reduction	in	cardiovascular	events	(expressed	as	NNT)	required	by	
the	patients	to	justify	taking	daily	preventive	medication.	
Bubble	graph	showing	the	percentage	of	participants	of	included	studies	that	could	accept	taking	a	medication	against	the	
number	of	individual	needed	to	be	treated	for	5	years	to	prevent	one	cardiovascular	event;	the	bubble	area	represents	the	
sample	size.	
 
	
  
 23 
Tables	
Table	1.	Characteristics	of	included	studies	
Study 
Participants: Sample Size 
(response rate%); Age; 
Women (%); data collection 
Participants Characteristics 
Settings 
Scenario: risk; medication; 
adverse event; side effects; 
cost 
Outcomes 
Carling, 
2008, 
Internet-
based46 
770 participants; 62% between 
40-59 years; 58% women; 
internet-based survey (in 
English) 
Community (18+; internet-
users); 90% educated to more 
than 12 years; 84% from 
USA; 23% GP or health 
professionals;  
Hypothetical; single choice 
experiment; high cholesterol 
level; daily statin-like; 10-year 
CV risk of angina or heart 
attack; side effects of statins; 
50US$ per month  
To decide whether to take the 
medication or not based on a 
single value of risk reduction 
(ARR, NNT) 
Carling, 
2009, 
Internet-
based29 
2978 participants; 54% 
between 40-59 years; 59% 
women; internet-based survey 
(in English and Norwegian) 
Community (18+; internet-
users); 91% educated to more 
than 12 years; 42% from USA 
Hypothetical; single choice 
experiment; high cholesterol 
level; daily statin-like; 10-year 
CV risk of angina or heart 
attack; side effects of statins; 
50US$ per month 
To decide whether to take the 
medication or not based on a 
single value of risk reduction 
(ARR or NNT) 
Carling, 
2010, 
Internet-
based26 
1528 participants; 49% 
between 40-59 years; 53% 
women; internet-based survey 
(in Norwegian) 
Community (18+; internet-
users); 59% educated to 
university-level 
Hypothetical; single choice 
experiment; 40-yr old, non-
smoker, active and has a 
healthy diet; high blood 
pressure level; daily; 10-year 
CV risk of stroke or heart 
attack; dizziness, impotence 
nausea, muscle cramps and 
others; co-payment 
To decide whether to take the 
medication or not based on a 
single value of risk reduction, 
framed both positively and 
negatively (ARR) 
Dahl, 2007, 
Denmark34 
1367 participants (50%); mean 
age 60; 52% women; in-person 
interview 
Community (40+); 32% had 
elementary education only; 
5% history of heart attack and 
18% hypercholesterolemia 
Hypothetical; single choice 
experiment; high cholesterol 
level; daily; heart attack; few 
and harmless side effects; 
60€ per year 
To decide whether to take the 
medication or not based on a 
single value of risk reduction 
(POL) 
Fontana, 
2014, UK10 
360 participants; mean age 38 
years; 50% women; face-to-
face interview 
Community; 22% on regular 
medications; 1% history of 
previous CVD  
Hypothetical; trade-off; high 
cholesterol level; daily statin-
like; CVD and death; no side 
effects; negligible 
Medical aversion (gain in 
lifespan required by participants 
to commence lifelong therapy); 
result was extracted from 
Figure1 
Fried, 2011, 
US30 
356 participants; mean age 76; 
75% women; in-person 
interview 
Community (senior centres); 
mean years of education was 
13; 69% had more than 3 
chronic conditions; 92% took 
1 or more medication, with a 
mean of 4 
Hypothetical; single choice 
experiment; multiple 
scenarios; primary CVD 
prevention; daily; 5-year MI 
risk; no side effects; covered 
by insurance 
To decide whether to take the 
medication or not based on a 
single value of risk reduction 
(ARR) + pictograph 
Goodyear-
Smith, 2008, 
New 
Zealand27 
100 participants (53%); mean 
66 years; 60% women; 
telephone interview 
Outpatients (4 family 
practices); patients eligible if 
they had heart disease and 
on statin;  
Hypothetical; single choice 
experiment; angina or heart 
attack; daily statin-like; 5-year 
heart attack risk; few side 
effects;  
To decide whether to take the 
medication or not based on a 
single value of risk reduction 
(ARR or NNT); negative 
framing 
Halvorsen, 
2005, 
Norway36 
1201 participants (60%); 43% 
between 25-44 year; 48% 
women; face-to-face (or 
telephone) interview 
Community; 28% educated 
more than 12 years; 11% 
history of hypertension, 8% 
hypercholesterolemia 
Hypothetical; multiple choice 
experiment; multiple 
scenarios; angina or heart 
attack; daily statin-like; heart 
To decide whether to take the 
medication or not based on a 
single value of risk reduction (3-
year NNT) 
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attack or stroke; no serious 
side effects; cost comparable 
to common cardio-preventive 
medication 
Halvorsen, 
2007, 
Norway19 
1397 participants (81%); mean 
58 years; 34% women; mailed 
questionnaire 
Community; 23% educated 
more than 12 years; 21% 
previous CVD history 
Hypothetical; single choice 
experiment; daily statin-like; 
heart attack; neither common 
nor dangerous side effects; 
refunded 
To decide whether to take the 
medication or not based on a 
single value of risk reduction (5-
year NNT, POL) 
Hudson, 
2012, New 
Zealand3 
354 participants (36%); mean 
60 years; 44% women; mailed 
questionnaire 
Outpatients (3GPs, all 
registered 50-70 years); 31% 
educated to high school only; 
13% previous CVD history 
 
Hypothetical; single choice 
experiment; daily; death; no 
major side effects; 3$ per 3 
months 
To choose, from six different 
estimates (10-year NNT), the 
number of lives should be 
saved to justify lifelong 
medication  
 
Hux, 1995, 
Canada9 
100 participants; 53% older 
than 55 years; 47% women; 
questionnaire 
Outpatients (35-65 years); 
55% take cardiovascular 
medications; 70% history of 
heart disease; 62% attended 
cardiology clinic 
Hypothetical; multiple choice 
experiment; daily statin-like; 
heart attack; negligible side 
effects; insured 
To decide whether to take the 
medication or not based on a 
single value of risk reduction (5-
year ARR, NNT, POL) 
Kristiansen, 
2002, 
Denmark35 
675 participants (60%); mean 
age 44 years; 51% women; 
face-to-face interview 
Community; 21% educated to 
elementary-level only; 3.3% 
previous CVD history 
Hypothetical; single choice 
experiment; daily; heart 
attack; few and mild side 
effects; co-payment 55$ per 
year 
To decide whether to take the 
medication or not based on a 
single value of risk reduction (3-
year NNT) 
Leaman, 
2001, UK47 
216 participants (41%); 40.5% 
between 50-69 years; 55% 
women; mailed questionnaire 
Outpatients (single GP); the 
mean age at which 
respondents finished 
education was 16.7 years; 
13% on antihypertensive 
medication; 2% previous MI 
Hypothetical; iterative 
process; anti-hypertensive 
daily; heart attack; some side 
effects; some payment 
To choose, from 6 different 
estimates (5-year NNT), the 
number of lives should be 
saved to justify lifelong 
medication; negative framing 
Marshall, 
2006, UK48  
203 participants; median age 
65; 13% women; face-to-face 
interview  
Outpatients (13 Practices, No 
CVD history); mean years of 
education 15.5; 34.5% on 
long-term oral medications; 
50% had less than 7.5% 5-
year coronary risk 
Hypothetical; multiple choice 
experiment; daily; heart 
disease; rare side effects;  
To decide whether to take the 
medication or not based on a 
single value of risk reduction (5-
year ARR); each one decide 6 
times 
McAlister, 
2000, 
Canada32 
74 participants (51%); mean 
age 49; 53% women; face-to-
face interview  
Outpatients (5 GPs and 4 
internists, mild hypertension; 
no overt CVD); 69% educated 
to more than 12 years; 65% 
on antihypertensive 
Hypothetical; multiple choice 
experiment; multiple 
scenarios; antihypertensive 
daily; death, MI, stroke;  
Iterative process to achieve the 
smallest benefit (ARR) that 
justify lifelong medication 
(MCID) 
Misselbrook, 
2001, UK31 
309 participants (102 
hypertensive, 207 
normotensive) (89%); aged 35-
65 years; mailed questionnaire 
Outpatients (single practice); 
patients excluded if illiterate, 
CVD, diabetes, disability, or 
mental illness  
Hypothetical; single choice 
experiment; anti-hypertensive-
like daily; stroke;  
To decide whether to take the 
medication or not based on a 
single value of risk reduction 
(ARR, NNT) 
Nexoe, 2005, 
Denmark37 
2326 participants (50%); mean 
age 47 years; 56% women; 
face-to-face interview 
Community; 26% educated to 
elementary-level 
Hypothetical; single choice 
experiment; multiple 
scenarios; daily; death or 
heart attack; out of pocket 
payment 
To decide whether to take the 
medication or not based on a 
single value of risk reduction 
(NNT) 
Nicholson, 
1999, UK49 
384 participants (53%); mailed 
questionnaire 
Outpatients (1 GP) Hypothetical; single choice 
experiment; statin-like daily; 
MI 
To choose, from 4 different 
estimates (5-year NNT), the 
number of lives should be 
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saved to justify lifelong 
medication 
Sorensen, 
2008, 
Denmark 
50 
1519 participants (49%); mean 
age 59; 53.9% women; face-
to-face interview 
Community; 6% previous 
heart attack; 17% 
hypercholesterolemia 
Hypothetical; single choice 
experiment; daily; death or 
heart attack; mild and 
harmless side effects; 45€ per 
year 
To decide whether to take the 
medication or not based on a 
single value of risk reduction (3-
year RRR with baseline risk) 
Steel, 2000, 
UK38 
58 participants (58%); 45% 41-
65 years old; 58% women  
Community (39 practices) Single choice experiment; 
anti-hypertensive medication 
To choose, from a five different 
estimates (5-year NNT), the 
number of lives should be 
saved to justify lifelong 
medication  
Stovring, 
2008, 
Denmark28 
1169 participants (37%); aged 
40-59; 57% women; face-to-
face interview 
Community; median years of 
education 13 years; 37% CVD 
history  
Hypothetical; single choice 
experiment; multiple 
scenarios; statin-like daily; 
fatal heart disease; out of 
pocket 
To decide whether to take the 
medication or not based on a 
single value of risk reduction 
(10-year ARR, NNT, POL) 
Trewby, 
2002, US33  
307 participants (97%); mean 
age 61 years; 42% women; 
face-to-face (or telephone) 
interview 
Both (3 groups: 1discharged 
from CCU; 2no MI history but 
on medication, 3neither 
history nor medication) 
Hypothetical; single choice 
experiment; statin-like daily; 
heart attack; safe 
Iterative process to achieve the 
minimum threshold (POL) that 
justify lifelong medication; 
extracted from Figure3 
